• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4-disubstituted thiazoles

Professional Introduction to 2-(4-methyl-1,3-thiazol-2-yl)acetamide (CAS No. 173739-73-6)

2-(4-methyl-1,3-thiazol-2-yl)acetamide is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by the CAS number 173739-73-6, has garnered considerable attention due to its potential applications in medicinal chemistry and drug development. The molecular structure of this compound incorporates a thiazole ring, which is a heterocyclic compound known for its broad spectrum of biological activities. The presence of the acetylamide functional group further enhances its pharmacological relevance, making it a valuable candidate for further research and development.

The thiazole moiety in 2-(4-methyl-1,3-thiazol-2-yl)acetamide plays a crucial role in its biological activity. Thiazole derivatives are well-documented for their antimicrobial, anti-inflammatory, and antifungal properties. Recent studies have highlighted the thiazole scaffold as a key component in the design of novel therapeutic agents. The methyl substituent at the 4-position of the thiazole ring contributes to the compound's stability and bioavailability, which are critical factors in drug formulation.

One of the most compelling aspects of 2-(4-methyl-1,3-thiazol-2-yl)acetamide is its potential in targeting various biological pathways. Research has indicated that this compound exhibits inhibitory effects on certain enzymes and receptors involved in inflammation and pain modulation. These findings have opened up new avenues for exploring its applications in treating chronic inflammatory disorders and neuropathic pain conditions. The acetylamide group not only contributes to the compound's solubility but also enhances its interaction with biological targets, making it an attractive scaffold for drug design.

In recent years, there has been a surge in interest regarding small molecules that can modulate immune responses. 2-(4-methyl-1,3-thiazol-2-yl)acetamide has shown promise in preclinical studies as an immunomodulatory agent. Its ability to interact with immune cells and modulate cytokine production suggests potential applications in autoimmune diseases and immunodeficiency disorders. The compound's unique chemical structure allows it to engage with multiple receptors and enzymes simultaneously, which is a desirable trait for developing multifunctional drugs.

The synthesis of 2-(4-methyl-1,3-thiazol-2-yl)acetamide involves multi-step organic reactions that highlight the expertise required in pharmaceutical chemistry. The process typically begins with the preparation of the thiazole core, followed by functionalization at the 4-position with a methyl group. Subsequent steps involve introducing the acetylamide group at the 2-position of the thiazole ring. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions have been employed to achieve high yields and purity levels. These synthetic strategies are crucial for ensuring that the final product meets the stringent requirements of pharmaceutical applications.

The pharmacokinetic properties of 2-(4-methyl-1,3-thiazol-2-yl)acetamide are another area of active investigation. Studies have focused on understanding how this compound is absorbed, distributed, metabolized, and excreted by the body. Efficient absorption from the gastrointestinal tract and good bioavailability are essential for a drug to be effective. Additionally, metabolic stability is crucial to ensure that the compound remains active long enough to exert its therapeutic effects without being rapidly degraded by enzymatic processes.

Electrostatic interactions between 2-(4-methyl-1,3-thiazol-2-yl)acetamide and biological targets play a pivotal role in determining its efficacy. Computational modeling techniques have been increasingly used to predict these interactions and optimize drug design. By leveraging molecular dynamics simulations and quantum mechanical calculations, researchers can gain insights into how this compound binds to its target proteins and modulates their function. Such computational approaches have significantly accelerated the drug discovery process by allowing virtual screening of thousands of compounds before experimental testing.

The safety profile of any pharmaceutical compound is paramount before it can be considered for clinical use. Toxicology studies on 2-(4-methyl-1,3-thiazol-2-yl)acetamide have been conducted to assess its potential side effects and determine safe dosage ranges. These studies involve both in vitro tests on cell cultures and in vivo experiments on animal models. Preliminary results suggest that this compound exhibits low toxicity at therapeutic doses but may cause adverse effects at higher concentrations. Understanding these safety parameters is crucial for developing dosing regimens that maximize therapeutic benefits while minimizing risks.

The regulatory landscape for approving new drugs is stringent and requires extensive documentation of a compound's safety and efficacy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive data from preclinical studies before granting approval for clinical trials. The journey from bench to market involves multiple stages of testing, including Phase I trials focusing on safety profiles followed by larger-scale Phase II and Phase III trials assessing efficacy among human patients.

The role of interdisciplinary collaboration cannot be overstated in advancing pharmaceutical research like that involving 2-(4-methyl-1,3-thiazol-2-yl)acetamide. Chemists work hand-in-hand with biologists, pharmacologists, and clinicians to develop compounds that address unmet medical needs effectively. This collaborative approach ensures that all aspects—chemical synthesis, biological activity, pharmacokinetics, safety profiles—are thoroughly evaluated before moving forward with clinical development.

In conclusion, 2-(4-methyl-1,3-thiazol...

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)